Skip to main content
SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD logo

SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD — Investor Relations & Filings

Ticker · 002864 ISIN · CNE1000032C9 LEI · 300300O9XS3Z7XCBAZ19 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2026-05-26 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002864

About SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD

https://www.pljt.com

SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD specializes in the research, development, manufacturing, and distribution of pharmaceutical products, with a primary focus on modern Chinese patent medicines. The company’s core portfolio includes treatments for orthopedics, rheumatology, cardiovascular diseases, and digestive disorders. Its flagship product, Panlong Qi Tablets, is widely recognized for treating bone and joint ailments. Beyond traditional Chinese medicine, the group produces chemical drugs and health-related consumer products. The organization integrates modern extraction and production technologies with traditional pharmacological principles to ensure product efficacy and safety. It maintains a comprehensive supply chain encompassing medicinal herb cultivation, advanced manufacturing facilities, and a nationwide marketing network.

Recent filings

Filing Released Lang Actions
北京瑞强律师事务所关于陕西盘龙药业集团股份有限公司2025年年度股东会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 72% confidence The document is a legal opinion letter from a law firm regarding the procedural legality of the 2025 annual general meeting (AGM), which includes detailed disclosure of each resolution’s vote tallies. It is not an audit report, financial report, or proxy statement, but serves to officially document and validate the AGM voting results. Therefore, it fits the ‘Declaration of Voting Results & Voting Rights Announcements (DVA)’ category.
2026-05-26 Chinese
关于2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement by Shaanxi Panlong Pharmaceutical Group Co., Ltd. detailing the 2025 annual shareholders meeting (AGM) resolutions, including attendance, voting methods, and vote counts on each agenda item. It provides the results of shareholder votes on various proposals. This is a classic Declaration of Voting Results & Voting Rights Announcement rather than the AGM presentation materials or a financial report, fitting the DVA category.
2026-05-26 Chinese
关于公司2026年股票期权激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 90% confidence The document is a company disclosure of its self-inspection report (“自查报告”) on insider information holders and incentive plan participants’ stock trading, required under Chinese securities regulations. It is a regulatory compliance announcement, not a financial report, plan proposal, or director-specific trading notice. It does not announce issuance of new shares or dividends, nor is it a proxy, earnings release, or management discussion. Therefore it best fits the catch-all “Regulatory Filings” category.
2026-05-26 Chinese
董事会薪酬与考核委员会关于2026年股票期权激励计划激励对象名单的公示情况说明及核查意见
Share Issue/Capital Change Classification · 75% confidence The document is an official board committee disclosure regarding the public notice and verification of the participant list for the company’s 2026 stock option incentive plan. It relates to the approval and implementation of an equity incentive scheme, which falls under announcements of planned share issues or capital changes. Therefore, it should be classified as a share issue/capital change filing.
2026-05-21 Chinese
北京瑞强律师事务所关于陕西盘龙药业集团股份有限公司2026年股票期权激励计划（草案）之法律意见书
Regulatory Filings Classification · 84% confidence The document is a legal opinion letter (法律意见书) issued by a law firm regarding the compliance and legality of a proposed 2026 stock option incentive plan for a listed company. It does not contain financial statements, earnings data, proxy solicitation materials, management changes, or ESG content. It is neither an annual/interim report nor an M&A or financing announcement. Instead, it is a specialized legal compliance filing to be disclosed to regulators and shareholders, fitting the catch-all category for miscellaneous regulatory filings. Therefore, it should be classified as Regulatory Filings (RNS).
2026-05-12 Chinese
2026年股票期权激励计划（草案）
Remuneration Information Classification · 80% confidence The document is the full text of the company’s 2026 Stock Option Incentive Plan (draft), detailing eligibility, grant size, vesting conditions, pricing, performance metrics and accounting treatment for management and employees. It is not a financial report, audit, or earnings release, but a detailed equity compensation/remuneration plan submitted for shareholder approval. This aligns with the Remuneration Information category (DEF 14A), which covers executive and employee compensation plans, rather than a simple announcement, governance code, or proxy notice.
2026-05-12 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.